Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals
Author
Abstract
Suggested Citation
DOI: 10.1007/s40264-017-0526-1
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
- Mary K. Olson, 2002. "Pharmaceutical Policy Change and the Safety of New Drugs," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 615-642.
- Olson, Mary K., 2004. "Are novel drugs more risky for patients than less novel drugs?," Journal of Health Economics, Elsevier, vol. 23(6), pages 1135-1158, November.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
- Light, Donald W. & Lexchin, Joel R., 2021. "Pharmaceuticals as a market for “lemons”: Theory and practice," Social Science & Medicine, Elsevier, vol. 268(C).
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Guy David & Sara Markowitz & Seth Richards-Shubik, 2010.
"The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation,"
American Economic Journal: Economic Policy, American Economic Association, vol. 2(4), pages 1-25, November.
- Guy David & Sara Markowitz & Seth Richards, 2009. "The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation," NBER Working Papers 14634, National Bureau of Economic Research, Inc.
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Ilke Onur & Magnus Söderberg, 2020. "The impact of regulatory review time on incremental and radical innovation: evidence from the high-risk medical device market," Journal of Regulatory Economics, Springer, vol. 57(2), pages 134-158, April.
- Abraham, John & Davis, Courtney, 2005. "A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy," Social Science & Medicine, Elsevier, vol. 61(5), pages 881-892, September.
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 219, WU Vienna University of Economics and Business.
- W. David Bradford & Andrew N. Kleit, 2015. "Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication," Health Economics, John Wiley & Sons, Ltd., vol. 24(7), pages 859-875, July.
- Nicolas Da Silva, 2020.
"Quantifier la qualité des soins. Une critique de la rationalisation de la médecine libérale française,"
Revue française de socio-Economie, La découverte, vol. 0(en lutte), pages 261-280.
- Nicolas Da Silva, 2017. "Quantifier la qualité des soins. Une critique de la rationalisation de la médecine libérale française," Revue française de socio-Economie, La découverte, vol. 0(2), pages 111-130.
- Nicolas da Silva, 2017. "Quantifier la qualité des soins : une critique de la « rationalisation » de la médecine libérale française," Post-Print hal-02306257, HAL.
- Jörg Mahlich & Arne Bartol & Srirangan Dheban, 2021. "Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis," Health Economics Review, Springer, vol. 11(1), pages 1-10, December.
- Paul Maliszewski & Elisabeth Larson & Charles Perrings, 2013. "Valuing the Reliability of the Electrical Power Infrastructure: A Two-stage Hedonic Approach," Urban Studies, Urban Studies Journal Limited, vol. 50(1), pages 72-87, January.
- Collins, J. Michael & Simon, Kosali I. & Tennyson, Sharon, 2013. "Drug withdrawals and the utilization of therapeutic substitutes: The case of Vioxx," Journal of Economic Behavior & Organization, Elsevier, vol. 86(C), pages 148-168.
- Hostenkamp, Gisela & Lichtenberg, Frank R., 2015.
"The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence,"
Social Science & Medicine, Elsevier, vol. 130(C), pages 162-171.
- Frank Lichtenberg & Gisela Hostenkamp, 2013. "The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence," CESifo Working Paper Series 4516, CESifo.
- Liang (Leon) Xu & Hui Zhao & Nicholas C. Petruzzi, 2021. "Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway," Manufacturing & Service Operations Management, INFORMS, vol. 23(1), pages 170-190, 1-2.
- Boakye, Derrick & Sarpong, David & Mordi, Chima, 2022. "Regulatory review of new product innovation: Conceptual clarity and future research directions," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
- Francisco Polidoro, 2020. "Knowledge, routines, and cognitive effects in nonmarket selection environments: An examination of the regulatory review of innovations," Strategic Management Journal, Wiley Blackwell, vol. 41(13), pages 2400-2435, December.
- Hostenkamp, Gisela & Fischer, Katharina Elisabeth & Borch-Johnsen, Knut, 2016. "Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark," Health Policy, Elsevier, vol. 120(12), pages 1404-1411.
More about this item
Keywords
Boxed Warning; Safety Action; Priority Review; Goal Date; Restricted Indication;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:40:y:2017:i:6:d:10.1007_s40264-017-0526-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.